RxSight (RXST) Depreciation & Amortization (CF) (2020 - 2026)

RxSight (RXST) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $834000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 7.47% year-over-year to $834000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 2.72% YoY) and the FY2025 annual result came in at $3.3 million, down 8.64% from the prior year.
• Depreciation & Amortization (CF) declined to $834000.0 in Q1 2026, from $851000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q3 2024 to a low of $515000.0 in Q4 2024.
• A 5-year average of $919823.5 and a median of $941000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) slumped 51.0% — and 2025, when it surged 65.24%.
• Tracing RXST's Depreciation & Amortization (CF) over 5 years: stood at $918000.0 in 2022, then grew by 14.49% to $1.1 million in 2023, then tumbled by 51.0% to $515000.0 in 2024, then surged by 65.24% to $851000.0 in 2025, then fell by 2.0% to $834000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $834000.0 (Q1 2026), $851000.0 (Q4 2025), and $854000.0 (Q3 2025), per Business Quant data.